Marker Therapeutics is trading at $1.10, up 5.77% after hours, with the catalyst unclear.
- It rose 13.04% in the regular session on October 16, closing at $1.04; the after-hours move extends that advance.
- No company press release dated October 16 appeared on its investor-relations page; its latest listed release was September 22. A same-day Zacks article reported an upgrade to Rank #1 (Strong Buy), citing rising earnings estimates, but did not establish it as the cause. Available evidence does not confirm a sector-wide explanation.